GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Novo Integrated Sciences Inc (NAS:NVOS) » Definitions » ROE %

Novo Integrated Sciences (Novo Integrated Sciences) ROE % : -47.99% (As of Feb. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Novo Integrated Sciences ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Novo Integrated Sciences's annualized net income for the quarter that ended in Feb. 2024 was $-10.98 Mil. Novo Integrated Sciences's average Total Stockholders Equity over the quarter that ended in Feb. 2024 was $22.89 Mil. Therefore, Novo Integrated Sciences's annualized ROE % for the quarter that ended in Feb. 2024 was -47.99%.

The historical rank and industry rank for Novo Integrated Sciences's ROE % or its related term are showing as below:

NVOS' s ROE % Range Over the Past 10 Years
Min: -507.69   Med: -36.95   Max: -3.04
Current: -48.56

During the past 13 years, Novo Integrated Sciences's highest ROE % was -3.04%. The lowest was -507.69%. And the median was -36.95%.

NVOS's ROE % is ranked worse than
85.29% of 612 companies
in the Healthcare Providers & Services industry
Industry Median: 4.115 vs NVOS: -48.56

Novo Integrated Sciences ROE % Historical Data

The historical data trend for Novo Integrated Sciences's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Integrated Sciences ROE % Chart

Novo Integrated Sciences Annual Data
Trend Dec14 Dec15 Dec16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.04 -17.81 -12.14 -99.29 -56.09

Novo Integrated Sciences Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.70 -22.25 -49.20 -77.36 -47.99

Competitive Comparison of Novo Integrated Sciences's ROE %

For the Medical Care Facilities subindustry, Novo Integrated Sciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Integrated Sciences's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's ROE % distribution charts can be found below:

* The bar in red indicates where Novo Integrated Sciences's ROE % falls into.



Novo Integrated Sciences ROE % Calculation

Novo Integrated Sciences's annualized ROE % for the fiscal year that ended in Aug. 2023 is calculated as

ROE %=Net Income (A: Aug. 2023 )/( (Total Stockholders Equity (A: Aug. 2022 )+Total Stockholders Equity (A: Aug. 2023 ))/ count )
=-13.215/( (22.305+24.816)/ 2 )
=-13.215/23.5605
=-56.09 %

Novo Integrated Sciences's annualized ROE % for the quarter that ended in Feb. 2024 is calculated as

ROE %=Net Income (Q: Feb. 2024 )/( (Total Stockholders Equity (Q: Nov. 2023 )+Total Stockholders Equity (Q: Feb. 2024 ))/ count )
=-10.984/( (23.583+22.189)/ 2 )
=-10.984/22.886
=-47.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Feb. 2024) net income data. ROE % is displayed in the 30-year financial page.


Novo Integrated Sciences  (NAS:NVOS) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Feb. 2024 )
=Net Income/Total Stockholders Equity
=-10.984/22.886
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-10.984 / 12.684)*(12.684 / 36.0965)*(36.0965 / 22.886)
=Net Margin %*Asset Turnover*Equity Multiplier
=-86.6 %*0.3514*1.5772
=ROA %*Equity Multiplier
=-30.43 %*1.5772
=-47.99 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Feb. 2024 )
=Net Income/Total Stockholders Equity
=-10.984/22.886
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-10.984 / -10.984) * (-10.984 / -6.16) * (-6.16 / 12.684) * (12.684 / 36.0965) * (36.0965 / 22.886)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.7831 * -48.57 % * 0.3514 * 1.5772
=-47.99 %

Note: The net income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Novo Integrated Sciences ROE % Related Terms

Thank you for viewing the detailed overview of Novo Integrated Sciences's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Integrated Sciences (Novo Integrated Sciences) Business Description

Traded in Other Exchanges
N/A
Address
11120 NE 2nd Street, Suite 100, Bellevue, WA, USA, 98004
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.
Executives
Sarfaraz Ali director C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Robert Letterio Oliva director 115 BELFIELD RD, TORONTO A6 L0J 1C0
Sterling M. Jimenez officer: Principal Financial Officer C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Michael Ross Pope director 1045 PROGRESS CIRCLE, LAWRENCEVILLE, GEORGIA GA 30043
Alex Flesias director 41 LANDMARK COURT, UNIONVILLE A6 L3R 9N7
Michael Joseph Gaynor director 49 BALMORAL ST, KEMPTVILLE A6 K0G 1J0
Robert Mattacchione director, 10 percent owner, officer: Chief Executive Officer 79 SELVAPIANO CRES, WOODBRIDGE A6 L4H 0X1
Pierre Joseph Dalcourt director, 10 percent owner 35 BRYANT ST , BOX 2230, HEARST A6 P0L 1N0
Christopher Mehlin David director, officer: President 10425 SE 22ND ST., BELLEVUE WA 98004
Thomas Edward Bray officer: Principal Financial Officer C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Rebecca Aw Mcdonald officer: Chief Accounting Officer 1301 INTERNATIONAL SPEEDWAY BLVD., DELAND FL 32724
James Jr Teters director 1200 FLIGHTLINE BLVD, STE 5, DELAN FL 32724
Phyllis Rouse officer: secretary 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Jay Hilden officer: President & CEO 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Robert Adamo director 1200 FLIGHTLINE BOULEVARD, SUITE 5, DELAND FL 32724